MEDCL MedinCell SA

Medincell: 25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI Clinical Phase 3

MONTPELLIER, France--(BUSINESS WIRE)--

Medincell’s (Paris:MEDCL) partner Teva Pharmaceuticals shared today as part of its Q3 2024 results, the following information:

About UZEDY®

  • Updated 2024 Revenue Outlook: Increased from $80 million to $100 million
    • U.S. Revenues Year-to-Date 2024: $75 million
    • U.S. Revenues for Q3 2024: $35 million
  • Medincell receives mid- to high-single digit royalties on all sales and is eligible for $105 million of commercial milestones

About Olanzapine Long-Acting Injectable (TV-‘749 / mdc-TJK)

  • Completion of 100% of targeted injections for submission without PDSS*

Teva Q3 results press release:

Teva Q3 2024 earnings conference call today at 8:00am ET, webcast and replay:

About Medincell

Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities.

UZEDY® and SteadyTeq™ are trademarks of Teva Pharmaceuticals

medincell.com

EN
06/11/2024

Underlying

MEDCLMedinCell SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MedinCell SA

 PRESS RELEASE
Free
MEDCL MEDINCELL SA

MedinCell : Information relative au nombre d’actions composant le capi...

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: MedinCell (Paris:MEDCL) : Place de cotation : Euronext Paris, Compartiment B Code ISIN : FR0004065605 Date Nombre de titres composant le capital en circulation Nombre total de droits de vote Total brut (1) Total net (2) 31 octobre 29 103 380 40 894 096 40 881 596 (1) Le nombre de droits de vote bruts (ou droits de vote “théoriques”) sert de base de calcul pour les franchissements de seuil. Conformément à l’article 223-11 du Règlement Général de l’AMF, ce nombre est calculé...

12h / 4m 1 FR
Oscar Haffen Lamm
  • Oscar Haffen Lamm
MEDCL MEDINCELL SA

MedinCell: Ready for its next Act

On the back of Teva's Q3'24 encouraging updates on Uzedy and mdc-TJK, and in view of its strong performance YTD (+126%), we believe our base case scenario is still not priced in, and that future upside on the name might currently be overlooked by investors. Firstly, since launch Uzedy has seen stro

11/07/24 November 7, 2024 1 EN
 PRESS RELEASE
Free
MEDCL MEDINCELL SA

Medincell: 25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Re...

MONTPELLIER, France--(BUSINESS WIRE)-- Medincell’s (Paris:MEDCL) partner Teva Pharmaceuticals shared today as part of its Q3 2024 results, the following information: About UZEDY® Updated 2024 Revenue Outlook: Increased from $80 million to $100 million U.S. Revenues Year-to-Date 2024: $75 million U.S. Revenues for Q3 2024: $35 million Medincell receives mid- to high-single digit royalties on all sales and is eligible for $105 million of commercial milestones About Olanzapine Long-Acting Injectable (TV-‘749 / mdc-TJK) Completion of 100% of targeted injections for submission with...

November 6, 2024 1 EN
 PRESS RELEASE
Free
MEDCL MEDINCELL SA

Medincell : prévision de revenus 2024 relevée de 25% pour UZEDY® et fr...

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: Teva Pharmaceuticals, partenaire de Medincell (Paris:MEDCL), a annoncé aujourd'hui lors de ses résultats du troisième trimestre 2024, les informations suivantes : A propos d’UZEDY® Nouvelle prévision de revenus pour 2024 : révision à la hausse de 80 à 100 millions de dollars Revenus aux États-Unis depuis le début de l'année 2024 : 75 millions de dollars Revenus aux États-Unis au troisième trimestre 2024 : 35 millions de dollars Medincell est éligible au versement de royalties « mid- to high-single digit » sur les ventes nettes...

November 6, 2024 1 FR
 PRESS RELEASE
Free
MEDCL MEDINCELL SA

Medincell’s Partner Teva Unveils New Phase 3 Positive Results for Olan...

MONTPELLIER, France--(BUSINESS WIRE)-- Medincell (Paris:MEDCL): TEV-‘749 / mdc-TJK - Investigational Olanzapine Long-Acting Injectable Teva presented positive data from the initial period of the Phase 3 SOLARIS trial evaluating Olanzapine LAI in adult patients diagnosed with schizophrenia. Findings demonstrate significant improvement in social functioning and quality of life across multiple validated measures from baseline to week 8. Data show that Medincell subcutaneous delivery technology underlying olanzapine LAI resulted in no occurrence of Post-Injection Delirium/Sedation Syndrom...

November 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch